Radiomics-based prediction of HCC response to atezolizumab/bevacizumab.

Oncol Lett · 2025 · PMC12373426 · PMID 40861099

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

slightly significantno p-value reported

Previous treatment had been received by 58.6% of patients in the DC group, with surgical resection (18.6%) and transarterial chemoembolization (TACE) (35.7%, P=0.038) being the most common interventions, TACE being slightly significant.

also in 1,762 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.